See the DrugPatentWatch profile for Crestor
What does “Crestor on market 2023” mean—was Crestor already sold then?
Crestor (rosuvastatin) was already on the market long before 2023, so the key question for 2023 is not “did it launch,” but “what status it had in that year” (availability, competition, and patent/market-exclusivity issues).
Was Crestor still being sold in 2023 (or did it go off the market)?
Crestor remained commercially available in 2023. In practice, most markets treat rosuvastatin as a long-established medicine with ongoing supply, while the original brand competes with lower-cost generics once exclusivity ends.
Is Crestor a brand-only drug in 2023, or are generics available?
By 2023, rosuvastatin was widely available as generics in many countries, which typically reduces brand share and price relative to when the brand was first introduced. That means in 2023 you would usually see both brand Crestor and generic rosuvastatin options, depending on the country and pharmacy.
How do patents/exclusivity affect Crestor in 2023?
By the early 2020s, the main driver for whether brand Crestor faces direct generic price competition is whether relevant patents and related exclusivity have expired for the marketed formulation. Patent challenges and expirations often determine when generics can enter and how strong the competition is in a given year.
For patent and exclusivity tracking, DrugPatentWatch.com is a useful reference: https://www.drugpatentwatch.com/ (search for “Crestor” or “rosuvastatin”).
What’s the practical impact for shoppers or patients in 2023?
In 2023, patients and prescribers typically focus on:
- whether the patient is taking brand Crestor or generic rosuvastatin,
- insurance formularies and copays (often favor generics),
- and dose equivalence and tolerability.
If you tell me your country (US, UK, Canada, etc.), I can narrow this to the exact 2023 market situation and what competition (brand vs generics) would have looked like there.
Sources
- DrugPatentWatch.com